The expression of the PI3K/AKT/mTOR pathway in gastric cancer and its role in gastric cancer prognosis
Open Access
- 1 September 2015
- journal article
- research article
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. 8, 2427-2433
Abstract
Objective: To analyze the correlation between sequential aspects of the phosphoinositide-3 kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway by immunohistochemistry in the primary lesion of gastric cancer, clinicopathologic factors, and survival in Chinese patients to explore the role of sequential analysis of multiple targets in prognoses. Methods: Immunohistochemistry was performed to examine the expression of PI3K, phosphorylated-AKT (p-AKT), and phosphorylated-mTOR (p-mTOR) in 59 primary lesion samples ranging from Stages I to IV after gastrectomy. The correlation between sequential expression of multiple targets, and clinicopathologic factors and survival was analyzed. Results: The positive expression rates of PI3K, p-AKT, and p-mTOR were 49%, 58%, and 56%, respectively. There were eleven cases with three biomarkers positive (19%), 22 cases with two biomarkers positive (37%), and 19 cases with only one biomarker positive (32%). Seven cases (12%) were all negative. Multi-factorial Cox regression analysis showed that neural invasion, vascular invasion, size of the tumor, lymph nodes affected, metastasis, carbohydrate antigen 19-9 level, and PI3K/p-AKT/p-mTOR simultaneous expression were independent prognostic parameters. The risk of death for the cases with two biomarkers positive was 0.367 times that for the cases with three biomarkers positive (P=0.166). The risk of death for the cases with only one biomarker positive was 0.105 times that for the cases with three biomarkers positive (P=0.058). The risk of death for the cases with three biomarkers negative was 0.017 times that for the cases with three biomarkers positive (P=0.022). Conclusion: Our study generated the hypothesis that patients with gastric cancer with simultaneous expression of PI3K/p-AKT/p-mTOR had worse outcome. But we need more rigorous validation in a larger data set.Keywords
This publication has 19 references indexed in Scilit:
- Comprehensive molecular characterization of gastric adenocarcinomaNature, 2014
- The challenge of targeted therapies for gastric cancer patients: the beginning of a long journeyExpert Opinion on Investigational Drugs, 2014
- Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 StudyJournal of Clinical Oncology, 2013
- Markers CD40, VEGF, AKT, PI3K, and S100 Correlate with Tumor Stage in Gastric CancerOncology Research and Treatment, 2013
- Roles of the PI3K/Akt pathway in Epstein-Barr virus-induced cancers and therapeutic implicationsWorld Journal of Virology, 2012
- Alterations in the human epidermal growth factor receptor 2-phosphatidylinositol 3-kinase-v-Akt pathway in gastric cancerWorld Journal of Gastroenterology, 2012
- Inhibition of mTOR Activates the MAPK Pathway in Glioblastoma Multiforme.2009
- Overexpression of Phosphorylated Mammalian Target of Rapamycin Predicts Lymph Node Metastasis and Prognosis of Chinese Patients with Gastric CancerClinical Cancer Research, 2009
- Effects of LY294002 on the invasiveness of human gastric cancer in vivo in nude miceWorld Journal of Gastroenterology, 2009
- The phosphatidylinositol 3-Kinase–AKT pathway in human cancerNature Reviews Cancer, 2002